基于总浓度与游离浓度群体方法为危重患儿制定环丙沙星个体化给药建议
这项前瞻性、开放标签、多中心群体药代动力学研究纳入44例接受静脉环丙沙星(10 mg/kg 每12小时)的危重患儿(<16岁),建立总浓度与游离浓度的群体PK模型并模拟不同剂量的靶标 attainment 概率(PTA)。环丙沙星清除率受肾小球滤过率正向影响、受机械通气负向影响。对MIC 0.25 mg/L,研究剂量下游离暴露(fAUC/MIC >72小时)PTA为75.3%,总暴露(AUC/MIC >125小时)PTA为79.7%。达到足够PTA(≥90%)需机械通气患儿10 mg/kg 每12小时,肾功能正常(80-130 mL/min/1.73m²)的非机械通气患儿15 mg/kg 每8小时(超说明书用药)。作者认为标准剂量在非机械通气、肾功能正常或增高的危重患儿中无法达到足够靶标,需进一步前瞻性研究强化给药方案的疗效与安全性。
要点
- 对MIC 0.25 mg/L,研究剂量10 mg/kg 每12小时下游离暴露(fAUC/MIC >72小时)PTA为75.3%,总暴露(AUC/MIC >125小时)PTA为79.7%。
- 达到足够PTA(≥90%)需机械通气患儿10 mg/kg 每12小时,肾功能正常(80-130 mL/min/1.73m²)的非机械通气患儿15 mg/kg 每8小时(超说明书用药)。
- 环丙沙星清除率受肾小球滤过率正向影响,机械通气时清除率负向影响。
- 标准剂量20-30 mg/kg/日无法在非机械通气、肾功能正常或增高的危重患儿中达到足够靶标 attainment。
- 作者建议进一步前瞻性评估强化环丙沙星给药方案的疗效与安全性。
适用人群与场景
- 危重患儿(<16岁)接受静脉环丙沙星治疗者,研究纳入44例。
诊断标准与关键阈值
- 靶标:对MIC 0.25 mg/L,游离暴露目标为fAUC/MIC >72小时,总暴露目标为AUC/MIC >125小时。
- 足够PTA定义为≥90%。
- 肾功能正常定义为肾小球滤过率80-130 mL/min/1.73m²。
处置流程与药物剂量
- 机械通气患儿:10 mg/kg 每12小时静脉给药以达到足够PTA(≥90%)。
- 非机械通气且肾功能正常(80-130 mL/min/1.73m²)患儿:15 mg/kg 每8小时静脉给药(超说明书用药)以达到足够PTA(≥90%)。
- 研究方案剂量为10 mg/kg 每12小时静脉给药,共两个给药 occasions。
研究设计与关键结果
- 研究类型:前瞻性、开放标签、多中心群体药代动力学研究;样本量44例危重患儿(<16岁);干预:静脉环丙沙星10 mg/kg 每12小时;主要终点:群体PK模型参数及PTA。
- 环丙沙星PK最佳描述为异速增长二室模型;血浆游离环丙沙星分数估计为0.52(IQR 0.49-0.56),尿中原型排泄分数为0.89(IQR 0.54-0.95)。
- 清除率受肾小球滤过率正向影响,机械通气时负向影响。
- 对MIC 0.25 mg/L,研究剂量下游离暴露(fAUC/MIC >72小时)PTA为75.3%,总暴露(AUC/MIC >125小时)PTA为79.7%。
- 达到足够PTA(≥90%)需机械通气患儿10 mg/kg 每12小时,肾功能正常(80-130 mL/min/1.73m²)的非机械通气患儿15 mg/kg 每8小时(超说明书用药)。
证据类型、等级与局限
- 证据类型:前瞻性、开放标签、多中心群体药代动力学研究。
- 局限:原文未报告局限性;作者指出需进一步前瞻性评估强化给药方案的疗效与安全性。
对床旁实践的改变
- 标准环丙沙星剂量(20-30 mg/kg/日)在非机械通气、肾功能正常或增高的危重患儿中可能无法达到足够靶标 attainment,作者认为需考虑强化给药方案。
- 机械通气患儿可按10 mg/kg 每12小时给药以达到足够PTA;肾功能正常(80-130 mL/min/1.73m²)的非机械通气患儿可考虑15 mg/kg 每8小时(超说明书用药),作者建议进一步前瞻性评估。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
OBJECTIVES: Optimal ciprofloxacin dosing in critically ill children is influenced by complex factors affecting drug disposition, including pathophysiological changes and supportive therapies. This study aimed to develop a population pharmacokinetic (PK) model for ciprofloxacin in critically ill children to identify predictors of interindividual variability, evaluate target attainment for both total and unbound exposure, and provide tailored dosing recommendations.
METHODS: A prospective, open-label, multicentric PK study was conducted in 44 critically ill children (<16 years) receiving intravenous ciprofloxacin. Blood and urine samples were collected at two dosing occasions (10 mg/kg every 12 hours) and drug concentrations were assessed in plasma (total and unbound concentrations) and urine. PK parameters were analysed with population PK modelling. Probability of target attainment (PTA) was calculated based on the free or total area under the curve (AUC) and was simulated for different doses of ciprofloxacin.
RESULTS: Ciprofloxacin PK was best described with an allometrically scaled two-compartment model. Typical fraction unbound ciprofloxacin in plasma, and the fraction excreted unchanged in urine were estimated to be 0.52 (IQR: 0.49-0.56) and 0.89 (IQR: 0.54-0.95), respectively. Clearance was found to be positively influenced by the glomerular filtration rate and negatively influenced when children were on mechanical ventilation. For a MIC of 0.25 mg/L, the study dose achieved a PTA of 75.3% for unbound exposure (fAUC/MIC >72 hours) and 79.7% for total exposure (AUC/MIC >125 hours). Adequate PTA (≥90%) requires 10 mg/kg every 12 hours in ventilated patients and 15 mg/kg every 8 hours (off-label) in nonventilated patients with normal renal function (80-130 mL/min/1.73m2).
DISCUSSION: Standard dosing regimens of ciprofloxacin (20-30 mg/kg per day) fail to achieve adequate target attainment in nonventilated critically ill children with a normal or elevated renal function. Further research should prospectively evaluate the efficacy and safety of intensified ciprofloxacin dosing regimens.
参考来源
- De Sutter PJ, Dhont E, Vens D, et al. Developing tailored dosing recommendations for ciprofloxacin in critically ill children using a population approach based on total and unbound concentrations. Clin Microbiol Infect. 2025. PMID: 40846052. doi:10.1016/j.cmi.2025.08.010
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。